Saiba GmbH

Share on: 
Website: Saiba GmbH
Business Area(s): 

With the effective control of infectious diseases in many parts of the world, chronic, often non-communicable diseases have become the single largest cause of death and disability.

Treatment of such chronic diseases is expensive and often ineffective. There is therefore a major need for novel treatment modalities to prevent rather than treat chronic diseases and that are available at affordable costs.

Inducing long-lived antibody responses by vaccination against endogenous molecules, which are normally targeted by monoclonal antibodies, represents a promising way to tackle this issue.

Saiba GmbH uses virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen.